Veracyte gains on data supporting prostate cancer test to guide treatment decisions
VCYT•Veracyte said its Decipher test identified intermediate-risk prostate cancer patients most likely to benefit from adding hormone therapy to radiation. Patients with intermediate or high scores saw an 8-percentage-point reduction in cancer spread at 10 years, while about 44% with low scores saw no significant benefit.
1. Test data findings
Veracyte said an analysis found its Decipher test identified intermediate-risk prostate cancer patients most likely to benefit from adding hormone therapy to radiation. Patients with intermediate or high Decipher scores saw an 8-percentage-point reduction in cancer spread at 10 years when hormone therapy was added.
2. Analysis details
About 44% of patients had low scores and saw no significant benefit from added hormone therapy. The findings were based on a retrospective analysis of 395 patients from a late-stage prostate cancer trial.
